| Patent application number | Description | Published |
|---|
| 20090014458 | POINT-OF-CARE MEDICATION DISPENSING - A medication dispenser is provided, comprising a securable container configured to store one or more doses of one or more medications and an access device configured to selectably permit access to the one or more doses. The medication dispenser further comprises an electronic interface configured to acquire user input from a user, and a processor configured to compare the user input to a database, to select, responsive to the comparing, an appropriate dose from the one or more doses, and to permit access through the access device to the appropriate dose. A method for dispensing medication is provided, comprising the steps of locating a medication dispenser at a point-of-care, acquiring user input from a user at the point-of-care, comparing the user input to a database, selecting, responsive to the comparing, an appropriate dose from the one or more doses, and permitting access through the access device to the appropriate dose. | 01-15-2009 |
| 20090108011 | MANAGING MEDICATIONS AT THE BEDSIDE - Systems and methods for dispensing medications to hospitalized individuals through a first apparatus containing optional medications that is configured to be replenished by optional medication from a central storage location. Some embodiments provide that the first apparatus is associated with an individual patient. The first apparatus is preferably secured at a location near the individual patient, such as, for example, within the individual patient's room. By creating multiple dispensing apparatuses, a caregiver who administers required medications no longer has to retrieve optional medications from a central storage location. | 04-30-2009 |
| Patent application number | Description | Published |
|---|
| 20090247567 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 10-01-2009 |
| 20110097349 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R | 04-28-2011 |
| 20110105464 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE - Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 05-05-2011 |
| 20110130363 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 06-02-2011 |
| 20110172216 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 07-14-2011 |
| Patent application number | Description | Published |
|---|
| 20110076291 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z | 03-31-2011 |
| 20110076292 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z | 03-31-2011 |
| 20120244149 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z | 09-27-2012 |
| Patent application number | Description | Published |
|---|
| 20120035208 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formula (I), and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer or inflammation mediated by lipid kinases. Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 02-09-2012 |
| 20120171199 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. | 07-05-2012 |
